State of Wyoming Invests $513,000 in Halozyme Therapeutics, Inc. $HALO

State of Wyoming acquired a new position in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) in the second quarter, according to its most recent Form 13F filing with the SEC. The firm acquired 6,557 shares of the biopharmaceutical company’s stock, valued at approximately $513,000.

Several other institutional investors and hedge funds have also recently bought and sold shares of the stock. Norges Bank purchased a new position in Halozyme Therapeutics during the fourth quarter worth about $128,201,000. William Blair Investment Management LLC acquired a new position in shares of Halozyme Therapeutics in the 4th quarter worth approximately $124,031,000. Voloridge Investment Management LLC purchased a new position in shares of Halozyme Therapeutics during the 3rd quarter worth approximately $77,587,000. Qube Research & Technologies Ltd purchased a new position in shares of Halozyme Therapeutics during the 2nd quarter worth approximately $51,295,000. Finally, Assenagon Asset Management S.A. increased its holdings in Halozyme Therapeutics by 4,578.9% in the 2nd quarter. Assenagon Asset Management S.A. now owns 997,643 shares of the biopharmaceutical company’s stock valued at $78,086,000 after purchasing an additional 976,321 shares during the last quarter. 97.79% of the stock is currently owned by hedge funds and other institutional investors.

Halozyme Therapeutics Stock Performance

Shares of Halozyme Therapeutics stock opened at $103.00 on Tuesday. The business has a 50-day simple moving average of $80.30 and a 200-day simple moving average of $72.79. The company has a debt-to-equity ratio of 13.50, a quick ratio of 2.31 and a current ratio of 2.71. Halozyme Therapeutics, Inc. has a one year low of $61.22 and a one year high of $104.78. The company has a market cap of $11.69 billion, a PE ratio of 30.75, a P/E/G ratio of 0.40 and a beta of 0.85.

Halozyme Therapeutics (NASDAQ:HALO) last issued its earnings results on Thursday, August 6th. The biopharmaceutical company reported $2.28 earnings per share for the quarter, beating the consensus estimate of $1.79 by $0.49. Halozyme Therapeutics had a net margin of 24.86% and a return on equity of 260.98%. The firm had revenue of $481.00 million for the quarter, compared to analysts’ expectations of $402.28 million. During the same quarter last year, the company earned $1.54 earnings per share. The firm’s revenue was up 47.7% compared to the same quarter last year. Halozyme Therapeutics has set its FY 2026 guidance at 8.650-9.000 EPS. On average, equities research analysts forecast that Halozyme Therapeutics, Inc. will post 7.77 EPS for the current fiscal year.

Insider Transactions at Halozyme Therapeutics

In related news, Director Mahesh Krishnan sold 7,304 shares of the business’s stock in a transaction on Monday, June 29th. The shares were sold at an average price of $75.00, for a total transaction of $547,800.00. Following the completion of the transaction, the director owned 14,462 shares in the company, valued at approximately $1,084,650. The trade was a 33.56% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Bernadette Connaughton sold 1,626 shares of the stock in a transaction on Monday, August 10th. The shares were sold at an average price of $102.80, for a total value of $167,152.80. Following the completion of the transaction, the director directly owned 40,418 shares in the company, valued at $4,154,970.40. This trade represents a 3.87% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders sold 44,103 shares of company stock valued at $3,142,896. Insiders own 2.50% of the company’s stock.

Wall Street Analyst Weigh In

A number of research firms have commented on HALO. Benchmark restated a “buy” rating on shares of Halozyme Therapeutics in a research note on Tuesday, July 21st. HC Wainwright boosted their price objective on Halozyme Therapeutics from $95.00 to $115.00 and gave the company a “buy” rating in a report on Friday, August 7th. Morgan Stanley cut their price objective on Halozyme Therapeutics from $96.00 to $93.00 and set an “overweight” rating on the stock in a report on Tuesday, May 12th. Citizens Jmp increased their target price on Halozyme Therapeutics from $92.00 to $93.00 and gave the stock a “market outperform” rating in a research note on Friday, August 7th. Finally, UBS Group restated a “buy” rating and set a $90.00 target price on shares of Halozyme Therapeutics in a report on Wednesday, June 3rd. Nine equities research analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $91.20.

Halozyme Therapeutics Profile

Halozyme Therapeutics, Inc is a biopharmaceutical company headquartered in San Diego, California, that specializes in the development and commercialization of novel drug-delivery technologies. Founded in 1998, Halozyme focuses on enabling subcutaneous administration of biologic therapies through its proprietary platforms. The company’s core mission is to improve patient access and convenience while maintaining efficacy and safety profiles comparable to or better than traditional routes of administration.

The company’s flagship technology, ENHANZE®, is based on recombinant human hyaluronidase PH20 (rHuPH20), an enzyme that transiently degrades hyaluronan in the extracellular matrix.